Nilai Buku saben Saham: hepionpharma.com (HEPA)

Hepion Pharmaceuticals management is focusing on conducting clinical trials of liver drugs. These developments rely on an AI ecosystem for genomic analysis, which creates a closed patent perimeter. Accounting data on the share price visualize equity minus debt, where the 0.23 level captures the current state. Expectations for early-stage therapy results and liquidity risks are already priced into the market quote.

When constructing a long-term portfolio, fundamental screening requires an assessment of the real value of assets minus all liabilities. This indicator measures the equity per share, reflecting the intrinsic value of the business, which for Hepion Pharmaceuticals (HEPA), with its bioinformatics platform and clinical developments, confirms the capitalization of innovations into the final book value per share.